A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay
Leuk Lymphoma
.
2021 Feb;62(2):478-481.
doi: 10.1080/10428194.2020.1830390.
Epub 2020 Nov 25.
Authors
Matthew L Chase
1
,
Reid Merryman
1
,
David C Fisher
1
,
Eric Jacobsen
1
,
Ann LaCasce
1
,
Caron Jacobson
1
,
Arnold Freedman
1
,
Matthew S Davids
1
,
Jennifer R Brown
1
,
Allison Jacob
2
,
Philippe Armand
1
,
Jennifer Crombie
1
Affiliations
1
Dana Farber Cancer Institute, Boston, MA, USA.
2
Adaptive Biotechnologies, Seattle, WA, USA.
PMID:
33236969
DOI:
10.1080/10428194.2020.1830390
No abstract available
Publication types
Letter
MeSH terms
Humans
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Neoplasm, Residual
Prospective Studies